NCT06417502 Observational Study of Pediatric Rheumatic and Immunologic Diseases in China: The CAPRID Registry
| NCT ID | NCT06417502 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Autoimmune Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2022-04-29 |
| Primary Completion | 2024-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2022-04-29 with a primary completion date of 2024-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
An observational, multi-center, longitudinal registry study for Chinese pediatric patients with rheumatic and immunologic diseases.
Eligibility Criteria
Inclusion Criteria: * Age \<= 18 years old * Diagnosed with rheumatic and immunologic diseases (including diffuse connective tissue diseases, arthritis, vasculitis, inborn errors of immunity) * Diagnosed and Treated in China Exclusion Criteria: * Disagreement of involving in this study by the patient or his/her family.
Contact & Investigator
Hongmei Song, MD
PRINCIPAL INVESTIGATOR
Peking Union Medical College Hospital
Frequently Asked Questions
Who can join the NCT06417502 clinical trial?
This trial is open to participants of all sexes, up to 18 Years, studying Autoimmune Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06417502 currently recruiting?
Yes, NCT06417502 is actively recruiting participants. Contact the research team at sihao.gao@gmail.com for enrollment information.
Where is the NCT06417502 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China, Beijing, China, Chongqing, China and 5 additional locations.
Who is sponsoring the NCT06417502 clinical trial?
NCT06417502 is sponsored by Peking Union Medical College Hospital. The principal investigator is Hongmei Song, MD at Peking Union Medical College Hospital. The trial plans to enroll 20,000 participants.